Background: In the era of improving overall survival rates of malignant diseases, the impact of a previous malignancy (PM) on treatment and outcome of lung cancer (LC) remains unclear. Methods: We reviewed all LC patients from our institution that were treated from 2004 to 2006 for the occurrence of LC with PM excluding patients with multiple primary LC. Results: A total of 444 and 2698 LC patients with and without a history of a PM were identified (prevalence of 14.1%). PM were most often located in breast (15.5%), prostate (14.9%), bladder (9.0%) and kidney (8.8%). Compared to never smokers, patients with nicotine consumption had more often a cancer history of prostate, gastrointestinal, and the head-neck region. The median interval until diagnosis of LC was 72.2 months (range 0e537 months) with most LC diagnosed 5 years after PM diagnosis. With a similar distribution of histology, stage and localization compared to controls, NSCLC patients with PM and stage IV disease showed a favorable overall survival (p < 0.0001). In contrast, SCLC patients had similar survival curves (n.s.). Conclusions: A considerable subgroup of LC patients has a history of PM that may indicate a favorable prognostic factor. However, these patients should be treated similar to other LC patients. ª
Introduction
Lung cancer remains among the most frequent human cancers and the leading cause of cancer-related deaths in the Western civilization with a median overall 5-year survival of only 15% [1] . Recently, besides the major histology types small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), further subgroups have been identified which may be treated differently. For example, molecular alterations such as EGFR mutations or evidence of EML4-ALK translocation indicate distinct molecular profiles with impact on clinical outcome [2, 3] . To date, increasing numbers of genes are being identified to have potential roles in the development of a malignancy including tumor suppressor genes and DNA-repair genes [4, 5] . Still, the understanding of molecular changes underlying the development of multiple cancers remains incomplete. Beside environmental factors and exposure to carcinogenic agents such as nicotine and alcohol, hereditary factors may also play an important role in this regard. As a hypothesis, presence of two or more malignancies in one patient may also suggest a specific pattern of molecular alterations. There is limited clinical information on treatment and outcome of lung cancer patients with a history of a previous malignancy (PM) [6] . A history of a PM might hamper the treatment of lung cancer by comorbidities or side effects caused by previous therapies. Most data reported so far has been generated in the last century and has been derived from low patient numbers from a long time period which may render conclusions difficult due to varying diagnostic procedures and therapeutic options. Hence, we reviewed our experience with lung cancer as a second primary malignancy in patients diagnosed and treated in our institution within a defined and recent time interval.
Patients and methods
Using the hospital information system and medical records, we reviewed all lung cancer patients who were seen in our institution between January 1st, 2004, and December 31st, 2006, for information on any further malignancies prior to the diagnosis of lung cancer. Other institutions were contacted for further data on PM being diagnosed elsewhere. Semi-malignant cancers (e.g. basal cell carcinoma) were not registered as previous malignancies as these were not supposed to have influence on prognosis and survival. The histological diagnosis of lung cancer was made by an experienced pathologist with the knowledge of the PM. The independence from the PM was confirmed by immunostaining, if necessary.
Data on patients with subsequent malignancies after diagnosis of lung cancer was excluded in this analysis and has been published elsewhere [7] . Patients with lung cancer as sole malignancy served as control group. All patients were predominantly treated for lung cancer in our clinic. Upon approval by the local Ethics Committee (S-411/2008), patients and their treating physicians were contacted, and the follow-up statuses were completed. The staging of lung cancer was performed according to the 6th edition of TNM criteria; however, all data was also analyzed using the 7th TNM classification. The smoking status was assessed at diagnosis of lung cancer. In agreement to others [8, 9] , the status of a former smoker was defined for patients with nicotine cessation of at least 6 months. Patients with total consumption of less than 100 were classified as neversmokers [10] .
Follow-up after therapy of lung cancer
All patients entered a follow-up program with 3-monthly visits for the first 2 years, 6-monthly visits after 2e5 years and yearly visits thereafter [11, 12] . In addition, SCLC patients were seen every 2 months for the first year. All follow-up visits included physical examination, lung function tests and a chest radiograph. In surgically treated patients, a CT scan was performed every 6 months for the first 2 years.
Statistical analysis
Quantitative variables were summarized with their mean or median. Two-sided analysis of variance and the c 2 -test were performed where appropriate. The census date was fixed after a medium follow-up period of 40.9 months for surviving patients. As end points, we used the date of death or survival at the last documented contact to the patient. Overall survival was defined as the interval between dates of diagnosis and death. Living patients were censored at the date of last clinical visit. The cause of death was identified by clinical means, since autopsy could not be performed on a routine basis. Patients who died of other causes as lung cancer were also censored. Calculations of survival were done performing Kaplan Meier analyses. Throughout, a p-value of <0.05 was considered to be statistically significant.
Results
A total of 444 lung cancer patients were identified with a history of a PM other than lung cancer. PM were most often located in breast (15.5%), prostate (14.9%), bladder (9.0%), and kidney (8.8%) ( Table 1) . Moreover, a control set was identified comprising 2698 patients who developed no previous or subsequent malignancy. At the end of data bank closure, a total of 6304 person-years (4393 person-years for males and 1911 person-years for females) of observation after diagnosis of lung cancer were noted. Characteristics of patients with and without a PM are displayed ( Table 2) . Since data on treatment of previous malignancies was sparse and heterogeneous, this factor could not be included in our subsequent analyses.
In 329 of total 444 patients with PM (74.1%) the smoking status could be determined. Similar to controls, most patients were current (51%) or former smokers (34%) with a mean exposure of 38.3 pack-years. There was no statistically significant correlation between smoking status and PM; however, relative to never smokers, current and former smokers tend to have more often a history of previous cancers of the prostate (17.6% versus 4.0%), gastrointestinal (13.2% versus 8.0%) and head-neck regions (16.8% versus 10.0%) (p Z 0.09). Similarly, the total nicotine consumption was highest in patients with previous cancer in the head-neck (median of 59.7 pack years; PY), gastro-intestinal (57.6 PY) and urogenital regions (48 PY).
Of 444 patients with a PM history, 389 and 55 developed NSCLC and SCLC after a median period of 68.5 and 95.6 months, respectively, resulting in a prevalence of lung cancer with PM of 14.1% (14.96% for NSCLC and 10.1% for SCLC). Patients with a previous head-neck cancer tend to develop more often subsequent NSCLC rather than SCLC (14.4% versus 5.4%), however, this difference was not statistically significant (p Z 0.06). Of these 68 patients with a previous head-neck cancer, 37 (54%) patients developed a second lung cancer with predominant squamous histology which was diagnosed as lung cancer based on immunohistochemical and clinical data. Interestingly, a large numbers of gynecological cancers and Hodgkin lymphomas were diagnosed more than 10 years before diagnosis of lung cancer.
Histology, stage distribution, localization of lung primaries and occurrence of metastases were not significantly different between investigated patients and controls (Table 3 ). In general, the stage-dependent treatment of lung cancer was similar in both groups which held also true for early stage NSCLC patients with PM and complete resection of their lung tumor. Patients with PM who underwent surgery had largely a lobectomy (46%) or an atypical resection (30%). In contrast, control patients underwent more often lobectomies (71%), while atypical resections were done in only 4%. Due to poor performance status or patient denial approximately 30% of stage IV patients were not treated with systemic therapy which was similar in patients with and without PM. Interestingly, 17.4% and 18.8% of stage IV lung cancer patients with and without PM underwent surgical treatment, respectively. The 25 patients with stage IV lung cancer and PM receiving surgery included 18 patients with single pulmonary metastasis and 1 patient with a solitary adrenal gland metastasis. All other procedures were done as palliative surgery. Again, this was similar in the control group.
Survival
Patients with PM had a median overall survival of 904 days (control group 543 days, p < 0.0001). Since nearly exclusively all deaths were caused by lung cancer, disease specific survival was similar to overall survival. The survival benefit hold true for NSCLC (median survival 1075 days versus 595 days; p < 0.0001; Fig. 1 Table 2 ). Compared to controls, female patients with PM had a more improved survival (1399 versus 587 days; p < 0.0001; Fig. 2a ) compared to male patients (677 days versus 531; p Z 0.099; Fig. 2b) . However, the interval between diagnosis of lung cancer and PM had no significant impact on differences in overall survival between patients with and without PM (data not shown). Interestingly, lung cancer patients with a previous gynecological malignancy had a significant better survival compared to patients with previous gastro-intestinal cancer (p < 0.001; data not shown).
Separated for stages of disease, patients with and without PM had a similar overall survival for stage IeIIIB lung cancers. However, patients with stage IV NSCLC and a history of PM had a significantly improved median overall survival (409 versus 276 days; p < 0.0001; Fig. 3 ) which was significant for both men (p Z 0.001) and women (p Z 0.001) (data not shown). When all cancers were reclassified using the 7th TNM classification, these differences in survival could be confirmed (p < 0.001, data not shown). The inclusion of surgical procedures into the treatment of stage IV NSCLC was associated with significantly better survival in both patients groups with and without PM (n Z 22; p < 0.001 and n Z 159; p Z 0.007, respectively). Still, the survival benefit for stage IV NSCLC patients with PM compared to controls hold true in both patients with or without surgery (p < 0.001 and p Z 0.005, respectively). Again, these findings were similar after tumor stage reclassification (data not shown).
Patients with three independent tumors
Forty-five of 444 (10.1%) patients (28 male, 17 female) developed a third malignancy (25 and 20 patients before and after the diagnosis of lung cancer, respectively) comprising prostate (n Z 10; 40%), bladder (n Z 5; 20%), breast (n Z 4; 16%), and second NSCLC tumors (n Z 5; 10%). In these patients, lung cancer was often diagnosed as stage I and II disease (49% versus 28% for controls). With a median overall survival of 1617 days patients with three independent malignancies lived more than three times longer than control patients (542 days, p < 0.0001).
Discussion
Few studies have been undertaken to evaluate the prevalence, treatment and outcome of lung cancer patients with a PM other than lung cancer. In patients with previous head and neck cancer and subsequent primary bronchial cancer, a poor prognosis has been reported with the comparison to literature data of lung cancer patients without PM [13] . As potential explanations, advanced age, and combined alcohol and tobacco abuse were raised. In contrast, other studies have marginally stated that a history of malignant disease does not influence overall prognosis at least in elderly patients with NSCLC undergoing surgery; however, the subsets subjected to survival analysis were small [14, 15] . Recently, in a collective comprising a total of 860 patients, an improved 5-year survival rate for lung cancer patients with PM compared to patients without another tumor has been described [16] . To unravel this conflicting data, we conducted the present study on a patient cohort which, to our knowledge, comprises the largest patient collective so far.
In the current study, the occurrence of lung cancer with a PM was 14.1% excluding patients with second lung cancer. In contrast, other studies reported on lower prevalence numbers between 8.2% and 10.2% analyzing markedly smaller patient numbers or defined patient subgroups such as surgically treated lung cancer patients [17e20]. Still, our primary selection criterion of recruiting exclusively patients from our center may have impacted our findings of the occurrence of lung cancer as second malignancy. Moreover, patients with a PM history may be screened more frequently leading to increased detection of lung cancer [21] . However, the occurrence for NSCLC with PM in our study of 15% is quite similar to data from Duchateau and colleagues who reported on a prevalence of 14.7% [16] . In contrast, the development of SCLC after PM seems to be lower than for NSCLC which is in congruence to others [17, 19] . Interestingly, some reports noted an increase of the prevalence of two or more malignancies over the past decades, possibly due to increase of life expectancy and better treatment options for both malignant and nonmalignant diseases [16, 18, 22] .
Tobacco consumption has been identified as a major risk factor of various solid cancers including lung, larynx, oral cavity, esophagus, colorectal, breast and bladder [23, 24] . However, we cannot draw solid conclusions on the impact of smoking on the development of the PM in our study. Genetic alterations have often been used to explain multiple malignancies resulting in the concept of "field cancerization" [25] . Consequently, a higher lung cancer incidence for patients with carcinomas of the head-neck region or bladder has been noted with cigarette smoking as a major risk factor [22, 25, 26] . For example, analyzing 2737 patients with multiple primary cancer within 1975e2002, the relative risk for developing intrathoracic cancer for patients with larynx and bladder carcinomas was described as 2.42 (2.08e2.81) and 1.50 (1.2e1.86), respectively [22] . Similarly in our study, lung cancer patients experienced a PM of larynx, pharynx, kidney, bladder and stomach more frequently compared to general cancer incidence data from 2006 in Germany [21] ; however, this finding was statistically not significant. Moreover, most lung cancer patients with PM had experienced nicotine consumption which was most evident in previous cancers of these areas.
In congruence to data from others, the majority of our patients developed lung cancer more than 5 years after the PM resulting in a higher median age at diagnosis of lung cancer compared to controls [16, 18] . However, the stage distribution of patients diagnosed with lung cancer within or after 5 years of occurrence of the PM was not significantly different. Still, follow-up programs of selected solid cancers should consider the development of lung carcinomas even after a longer period of time.
In our study, patients with a history of PM and stage IeIIIB lung cancer had an outcome similar to control patients which, in turn, demonstrated comparable results in Figure 1 Survival curves of NSCLC patients with and without a previous malignancy (PM). Patients with PM had a significantly improved overall survival (median survival 1075 days versus 595 days; p < 0.0001).
relation to published data [27e29]. Regarding stage specific treatment modalities, no significant differences were found which is in congruence to others [16] . However, atypical resections were performed more often in patients with PM while lobectomy was the most frequent surgical method in control patients. In patients with stage IV NSCLC, a history of PM seems to be a favorable prognostic factor. This finding which is somewhat confirmed by the favorable outcome of patients with three independent tumors may be explained by several hypotheses: For example, metastatic disease may rather reflect the biology of the disease compared to lower stages which is generally treated with surgery or radiation. Also, various epigenetic and genetic alterations are known to modify lung cancer risk and development [5, 30] . Hence, the better overall survival of patients with PM may indicate a distinct epigenetic profile. Finally, the origin of the previous malignancy may further influence the course of subsequent lung cancer since a previous gynecological malignancy was correlated with a better survival compared to lung cancer patients with previous gastrointestinal cancers. However, one needs to consider the small patient numbers for this finding. Also, these hypotheses would be needed to be addressed in preclinical models with the focus also on epigenetic marks and gene expression changes. Moreover, since data on performance status was not available, a possible bias cannot be excluded.
As an additional finding, patient treated with surgery had a favorable outcome in both stage IV NSCLC patients with and without PM. While some patients with stage IV would have been classified as stage III according to current staging criteria this finding may encourage to conduct further studies addressing the role of surgery in stage IV disease. For some patients with single adrenal gland metastasis or limited number of cerebral secondaries, a potential benefit from complete resection of both lung primary and metastasis as a curative approach has been suggested [31, 32] . Whether palliative resection may be indicated for highly selected stage IV NSCLC patients remains speculative.
Conclusion
In conclusion, presence of PM should be treated similar to lung cancer as single malignancy. Despite to the unfavorable fact of having developed a second cancer, a history of PM does not significantly impair treatment options and outcome of lung cancer but may be even associated with an improved survival.
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